D

Duopharma Biotech Bhd
KLSE:DPHARMA

Watchlist Manager
Duopharma Biotech Bhd
KLSE:DPHARMA
Watchlist
Price: 1.23 MYR
Market Cap: 1.2B MYR
Have any thoughts about
Duopharma Biotech Bhd?
Write Note

Duopharma Biotech Bhd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Duopharma Biotech Bhd
Interest Income Expense Peer Comparison

Comparables:
P
PLABS
A
AHEALTH
R
RHONEMA
Y
YSPSAH
K
KOTRA

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
D
Duopharma Biotech Bhd
KLSE:DPHARMA
Interest Income Expense
-myr20m
CAGR 3-Years
-51%
CAGR 5-Years
-17%
CAGR 10-Years
-70%
P
PeterLabs Holdings Bhd
KLSE:PLABS
Interest Income Expense
-myr823k
CAGR 3-Years
-10%
CAGR 5-Years
-4%
CAGR 10-Years
-15%
A
Apex Healthcare Bhd
KLSE:AHEALTH
Interest Income Expense
myr20.9m
CAGR 3-Years
51%
CAGR 5-Years
21%
CAGR 10-Years
N/A
R
Rhone Ma Holdings Bhd
KLSE:RHONEMA
Interest Income Expense
-myr1.5m
CAGR 3-Years
-5%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Y
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Interest Income Expense
-myr890k
CAGR 3-Years
18%
CAGR 5-Years
14%
CAGR 10-Years
-16%
K
Kotra Industries Bhd
KLSE:KOTRA
Interest Income Expense
-myr37k
CAGR 3-Years
N/A
CAGR 5-Years
57%
CAGR 10-Years
42%

See Also

What is Duopharma Biotech Bhd's Interest Income Expense?
Interest Income Expense
-20m MYR

Based on the financial report for Jun 30, 2024, Duopharma Biotech Bhd's Interest Income Expense amounts to -20m MYR.

What is Duopharma Biotech Bhd's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
-70%

Over the last year, the Interest Income Expense growth was -85%. The average annual Interest Income Expense growth rates for Duopharma Biotech Bhd have been -51% over the past three years , -17% over the past five years , and -70% over the past ten years .

Back to Top